HomeCompareORPHY vs ORCC

ORPHY vs ORCC: Dividend Comparison 2026

ORPHY yields 6666.67% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORPHY wins by $1028095347812062.00M in total portfolio value
10 years
ORPHY
ORPHY
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full ORPHY calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — ORPHY vs ORCC

📍 ORPHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORPHYORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORPHY + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORPHY pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPHY
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, ORPHY beats the other by $848,834,263,535,826,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPHY + ORCC for your $10,000?

ORPHY: 50%ORCC: 50%
100% ORCC50/50100% ORPHY
Portfolio after 10yr
$514047673906031.00M
Annual income
$499,314,272,668,133,360,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

ORPHY
No analyst data
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPHY buys
0
ORCC buys
0
No recent congressional trades found for ORPHY or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORPHYORCC
Forward yield6666.67%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1028095347812062.00M$21.4K
Annual income after 10y$998,628,545,336,266,700,000.00$1.04
Total dividends collected$1026118102492338.88M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ORPHY vs ORCC ($10,000, DRIP)

YearORPHY PortfolioORPHY Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$677,367$666,666.67$11,190$489.61+$666.2KORPHY
2$42,928,313$42,203,530.63$12,229$256.01+$42.92MORPHY
3$2,545,616,701$2,499,683,405.64$13,216$130.74+$2545.60MORPHY
4$141,255,910,403$138,532,100,533.89$14,207$66.02+$141255.90MORPHY
5$7,335,374,338,812$7,184,230,514,680.15$15,234$33.17+$7335374.32MORPHY
6$356,516,885,536,661$348,668,034,994,132.70$16,317$16.62+$356516885.52MORPHY
7$16,218,956,689,966,618$15,837,483,622,442,392.00$17,468$8.32+$16218956689.95MORPHY
8$690,711,023,145,868,900$673,356,739,487,604,600.00$18,695$4.16+$690711023145.85MORPHY
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$20,006$2.08+$27539067734387.96MORPHY
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$21,407$1.04+$1028095347812062.00MORPHY

ORPHY vs ORCC: Complete Analysis 2026

ORPHYStock

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Full ORPHY Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this ORPHY vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPHY vs SCHDORPHY vs JEPIORPHY vs OORPHY vs KOORPHY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.